Cytokinetics (CYTK) CEO receives new RSU and stock option awards

Rhea-AI Filing Summary

Cytokinetics President & CEO Robert I. Blum reported equity awards and updated holdings. On March 15, 2026, he received an annual grant of 75,258 shares of common stock as restricted stock units that convert 1:1 into common shares.

These RSUs vest 40% on the first anniversary of the grant date, another 40% on the second anniversary, and the remaining 20% on the third, subject to continued employment under the company’s Amended and Restated 2004 Equity Incentive Plan. He was also granted 1,665 incentive stock options and 111,864 non-qualified stock options at an exercise price of $60.06 per share, vesting in 48 equal monthly installments and expiring on March 14, 2036. Following these awards, his direct common stock holdings total 466,931 shares. Indirectly, 2,083 shares are held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares by The Brittany Blum 2003 Irrevocable Trust.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Blum Robert I

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/15/2026		A(1)		75,258	A	$0	466,931	D
Common Stock								2,083	I	by Trust 1(2)
Common Stock								2,083	I	by Trust 2(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Stock Option (Right to Buy)	$60.06	03/15/2026		A(4)		1,665		04/15/2026	03/14/2036	Common Stock	1,665	$0	1,665	D
Non-Qualified Stock Option (Right to Buy)	$60.06	03/15/2026		A(5)		111,864		04/15/2026	03/14/2036	Common Stock	111,864	$0	111,864	D

Explanation of Responses:

1. Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan.

2. Shares held by The Bridget Blum 2003 Irrevocable Trust.

3. Shares held by The Brittany Blum 2003 Irrevocable Trust.

4. Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.

5. Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Blum	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did CYTK CEO Robert Blum receive on March 15, 2026?

Robert Blum received an annual grant of 75,258 restricted stock units plus 1,665 incentive stock options and 111,864 non-qualified stock options at an exercise price of $60.06 per share, all under Cytokinetics’ Amended and Restated 2004 Equity Incentive Plan.

How do Robert Blum’s new CYTK restricted stock units vest?

The 75,258 RSUs vest over three years: 40% on the one-year anniversary of the grant date, another 40% on the two-year anniversary, and the final 20% on the three-year anniversary, conditioned on his continued employment with Cytokinetics throughout the vesting period.

What are the terms of Robert Blum’s new Cytokinetics stock options?

Blum’s 1,665 incentive and 111,864 non-qualified stock options have a $60.06 exercise price and vest in 48 equal monthly installments, subject to continued employment. The options expire on March 14, 2036, and are granted under Cytokinetics’ Amended and Restated 2004 Equity Incentive Plan.

How many CYTK common shares does Robert Blum hold directly after these awards?

After the March 15, 2026 awards, Robert Blum directly holds 466,931 shares of Cytokinetics common stock. This figure reflects his updated direct ownership reported in the Form 4 and does not include additional indirect holdings held through irrevocable trusts.

What indirect CYTK holdings related to Robert Blum are reported via trusts?

The filing reports 2,083 Cytokinetics common shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust, both listed as indirect ownership entries associated with Robert Blum on the Form 4.

Are Robert Blum’s new CYTK equity awards tied to continued employment?

Yes. Both the RSU and stock option awards vest only if Robert Blum remains employed by Cytokinetics through the applicable vesting dates, as specified in the Form 4 footnotes and governed by the company’s Amended and Restated 2004 Equity Incentive Plan.